Related Experiment Video

Updated: Jul 2, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Cardiac resynchronization therapy modifies the neurohormonal profile, hemodynamic and functional capacity in heart

Endrj Menardi1, Antonello Vado, Guido Rossetti

  • 1Department of Cardiovascular Diseases, Ospedale S. Croce-Carle, Cuneo, Italy.

Archives of Medical Research
|September 2, 2008
PubMed

Insights

Cardiac resynchronization therapy (CRT) significantly improves heart failure symptoms and survival by favorably altering neurohormonal profiles, including reduced brain natriuretic peptide (BNP) and big endothelin (big-END) levels after one year.

Area of Science:

  • Cardiology
  • Heart Failure Management
  • Biomarkers

Background:

  • Congestive heart failure (CHF) patients treated with cardiac resynchronization therapy (CRT) show improved clinical status and survival.
  • The impact of CRT on the neurohormonal profile in CHF patients remains largely unexplored.

Purpose of the Study:

  • To investigate the effects of CRT on the neurohormonal profile in patients with moderate to severe heart failure.
  • To assess changes in key neurohormonal markers and functional parameters after CRT implantation.

Main Methods:

  • A study involving 120 NYHA II-IV heart failure patients indicated for CRT.
  • Patients underwent echocardiography, cardiopulmonary testing, and neurohormonal profiling (BNP, END, big-END, EPI, TNF-alpha) at baseline and 1-year post-implantation.
  • A control group of 20 patients who refused CRT was included for comparison.

Main Results:

  • CRT significantly improved NYHA class, left ventricular ejection fraction, mitral regurgitation severity, and peak VO2 in the treatment group (n=100).
  • Plasma levels of brain natriuretic peptide (BNP) and big endothelin (big-END) were significantly reduced in the CRT group after one year.
  • No significant changes in these parameters were observed in the control group (n=20).

Conclusions:

  • CRT is effective in improving clinical status and functional parameters in moderate to severe heart failure patients.
  • CRT positively modifies the neurohormonal profile, with significant reductions in BNP and big-END observed at one-year follow-up.
Abstract

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...